JP2018524361A - 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤 - Google Patents

抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤 Download PDF

Info

Publication number
JP2018524361A
JP2018524361A JP2018500814A JP2018500814A JP2018524361A JP 2018524361 A JP2018524361 A JP 2018524361A JP 2018500814 A JP2018500814 A JP 2018500814A JP 2018500814 A JP2018500814 A JP 2018500814A JP 2018524361 A JP2018524361 A JP 2018524361A
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
represented
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018500814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524361A5 (enExample
Inventor
昌浩 徳永
昌浩 徳永
俊彦 石井
俊彦 石井
元弥 三重
元弥 三重
宗稔 安藤
宗稔 安藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of JP2018524361A publication Critical patent/JP2018524361A/ja
Publication of JP2018524361A5 publication Critical patent/JP2018524361A5/ja
Priority to JP2021142739A priority Critical patent/JP7366093B2/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2018500814A 2015-07-14 2016-07-14 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤 Ceased JP2018524361A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021142739A JP7366093B2 (ja) 2015-07-14 2021-09-01 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192173P 2015-07-14 2015-07-14
US62/192,173 2015-07-14
PCT/JP2016/003337 WO2017010106A1 (en) 2015-07-14 2016-07-14 A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021142739A Division JP7366093B2 (ja) 2015-07-14 2021-09-01 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤

Publications (2)

Publication Number Publication Date
JP2018524361A true JP2018524361A (ja) 2018-08-30
JP2018524361A5 JP2018524361A5 (enExample) 2019-08-08

Family

ID=57757291

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018500814A Ceased JP2018524361A (ja) 2015-07-14 2016-07-14 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤
JP2021142739A Active JP7366093B2 (ja) 2015-07-14 2021-09-01 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021142739A Active JP7366093B2 (ja) 2015-07-14 2021-09-01 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤

Country Status (10)

Country Link
US (2) US20180271861A1 (enExample)
EP (2) EP3991749A3 (enExample)
JP (2) JP2018524361A (enExample)
KR (1) KR102823683B1 (enExample)
CN (1) CN107847597A (enExample)
AU (1) AU2016293667A1 (enExample)
CA (1) CA2992238A1 (enExample)
HK (1) HK1252514A1 (enExample)
TW (1) TW201713332A (enExample)
WO (1) WO2017010106A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111050797B (zh) 2017-07-28 2024-04-30 凡恩世制药(北京)有限公司 抗tim-3抗体及其用途
EP3843734A4 (en) * 2018-08-29 2022-05-25 ChemoCentryx, Inc. Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
KR20230152715A (ko) 2021-03-05 2023-11-03 유니버시타트 바셀 Ebv 관련 질환 또는 질병의 치료용 조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126066A1 (ja) * 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
JP2011527686A (ja) * 2008-07-08 2011-11-04 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
WO2011142316A1 (ja) * 2010-05-10 2011-11-17 協和発酵キリン株式会社 キヌレニン産生抑制作用を有する含窒素複素環化合物
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
WO2014186035A1 (en) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US603A (en) 1838-02-15 Improvement in the construction of many-chambered fire-arms
US5821A (en) 1848-10-03 Cream-freezer
US171A (en) 1837-04-20 Machine for washing iron and other ores
US4968A (en) 1847-02-13 Spinal elevator
US5677A (en) 1848-07-25 Improvement in hillside-plows
US337A (en) 1837-07-31 Mode of constructing railroad-frogs
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
WO1999029852A1 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
JP3926153B2 (ja) 2000-03-03 2007-06-06 協和醗酵工業株式会社 遺伝子組換え抗体およびその抗体断片
MXPA04001894A (es) 2001-08-31 2005-09-08 Kyowa Hakko Kogyo Kk Anticuerpo humano injertado en una cdr y fragmento de dicho anticuerpo.
WO2003063792A2 (en) 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
WO2005057341A2 (en) 2003-12-02 2005-06-23 Koolspan, Inc. Automatic hardware-enabled virtual private network system
SG195607A1 (en) 2005-05-10 2013-12-30 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
CA2682382A1 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
PT4160212T (pt) 2008-01-15 2024-06-25 Univ Leland Stanford Junior Marcadores de células estaminais de leucemia mielóide aguda
US8673908B2 (en) 2008-11-10 2014-03-18 Kyowa Hakko Kirin Co., Ltd. Kynurenine production inhibitor
JP5709061B2 (ja) 2009-09-10 2015-04-30 協和発酵キリン株式会社 ヒトｃｃケモカイン受容体４（ｃｃｒ４）に特異的に結合する抗体組成物を含む医薬
WO2011042065A1 (en) 2009-10-09 2011-04-14 Daniel Monsch "momoheli" lifting module and vehicles
US9067923B2 (en) 2011-11-09 2015-06-30 Kyowa Hakko Kirin Co., Ltd. Substituted quinoxalines
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
CN109810104B (zh) * 2013-11-08 2022-05-03 因赛特控股公司 用于合成吲哚胺2,3-双加氧酶抑制剂的方法
EP3153178A4 (en) 2014-06-06 2017-12-20 Kyowa Hakko Kirin Co., Ltd. Method for treating cancer patients using folr1 targeted drug and antifolate, and drug

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011527686A (ja) * 2008-07-08 2011-11-04 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
WO2010126066A1 (ja) * 2009-04-27 2010-11-04 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗IL-3Rα抗体
WO2011142316A1 (ja) * 2010-05-10 2011-11-17 協和発酵キリン株式会社 キヌレニン産生抑制作用を有する含窒素複素環化合物
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
WO2014087863A1 (ja) * 2012-12-07 2014-06-12 協和発酵キリン株式会社 抗ｆｏｌｒ１抗体
WO2014186035A1 (en) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibitors of the kynurenine pathway

Also Published As

Publication number Publication date
KR20180025897A (ko) 2018-03-09
US20220088011A1 (en) 2022-03-24
WO2017010106A1 (en) 2017-01-19
EP3991749A3 (en) 2022-08-24
EP3322444A1 (en) 2018-05-23
JP2021191780A (ja) 2021-12-16
JP7366093B2 (ja) 2023-10-20
HK1252514A1 (zh) 2019-05-31
AU2016293667A1 (en) 2018-01-04
EP3991749A2 (en) 2022-05-04
CN107847597A (zh) 2018-03-27
EP3322444A4 (en) 2019-06-12
KR102823683B1 (ko) 2025-06-23
US20180271861A1 (en) 2018-09-27
CA2992238A1 (en) 2017-01-19
TW201713332A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
JP7366093B2 (ja) 抗体と併用投与されるｉｄｏ阻害剤含有腫瘍治療剤
JP2023512837A (ja) Ｃｃｒ８に結合する抗体及び融合タンパク質並びにそれらの使用
CN114206855A (zh) 用于Cbl-b抑制的氰基环丁基类化合物及其用途
CN105339009B (zh) 用于治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
JP2020530495A (ja) Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法
JP7312706B2 (ja) 血液悪性腫瘍に対するｃｄ４７標的化治療のための投与パラメータ
CN107810011A (zh) 使用抗ox40抗体治疗癌症的方法
JP2017503001A (ja) がんを処置するための療法
RS59738B1 (sr) Anti-ox40 antitela i postupci primene
JP2016537433A (ja) 骨髄増殖性障害を処置するための治療
CN115920034A (zh) 用于治疗急性骨髓性白血病的cd70和bcl-2抑制剂的组合疗法
WO2020185739A1 (en) Anti-icos antibodies for the treatment of cancer
JP2023539589A (ja) Ｅｇｆｒ変異を有する非小細胞肺がんの治療
Jabbarzadeh Kaboli et al. c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity
KR20230061421A (ko) Bcl-2 억제제에 대한 감소된 민감도를 가진 환자를 치료하는 방법
JP7492752B2 (ja) 免疫療法のためのアジュバントとしてのグアナベンズ
JP2024509501A (ja) 新規活性を持つｈｈｌａ２結合剤
JP2022512860A (ja) 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
US20240141436A1 (en) Compounds, Compositions and Methods of Treatment Thereof
JP2020507576A (ja) Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
TW202416995A (zh) 用於治療與至少一種抗體分泌細胞標記物之表現相關的疾病的腺苷受體拮抗劑及其組合物
Recasens Zorzo Preclinical evaluation of the antitumor activity of a new CXCR4 inhibitor: a novel therapeutic approach in diffuse large B-cell lymphoma
HK1227043B (zh) 抗ox40抗体和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210304

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210803

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20211221